Tracers / [225Ac]Ac-DOTA-anti-CD33
[225Ac]Ac-DOTA-anti-CD33
Also written as [Ac-225]DOTA-anti-CD33
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- clinical stage
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated anti-CD33 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- CD33 PMID 41282197
- Clinical application
- Radioimmunotherapy for Acute Myeloid Leukemia PMID 41282197
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 40 ± 0.45 % | more than 98% | DOTA-anti-CD33 Creative Biolabs | 41282197 2025 Res Sq For radiolabeling of DOTA-anti-CD33 with 225Ac, an aliquot of 4 μL (approx. 1.11 MBq) of Ac-225 was added to a vial — [225Ac]DOTA-anti-CD33 was obtained with a radiochemical yield of 40 ± 0.45 % yield (n = 4 syntheses) with a radiochemical purity of more than 98% |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-anti-CD33, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41282197: 'DOTA-anti-CD33'. Stage set/updated at stage 23 from PMID 41282197: 'including [225Ac]DOTA-anti-CD33, a clinical stage-radioimmunotherapy under evaluation in AML'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.